Sepracor news from FierceBiotech
NewsSepracor inks $47M IP licensing deal with Arrow
Sepracor has struck a licensing deal with Arrow International Limited for the intellectual property rights related to stable sterile steroid suspension formulations and other applicable nebule Read more...
SPOTLIGHT: Sepracor licenses epilepsy drug rights
Sepracor is shelling out $75 million up front to license the marketing rights for an experimental epilepsy drug from Portugal's Bial. Sepracor will pay up to $100 million more in developmental and Read more...
ALSO NOTED: Paion inks $102M deal; Sepracor chairman plans retirement years;and much more...
> Sepracor Chairman Timothy Barberich is planning to retire. He will receive $1.65 million a year under a retirement pact. Read more...
ALSO NOTED: Cipla, Akorn in development deal; No charges in Sepracor probe; Vectura raises funds; and much more...
> The FDA has warned GSK that its marketing for the breast cancer drug Tykerb is out of hand. Report Read more...
ALSO NOTED: More takeover targets for Big Pharma; Byetta trial delivers positive data; and much more...
> Industry watchers can't resist identifying takeover targets for Big Pharma. This week, the Motley Fool's radar is picking up Sepracor--which announced layoffs yesterday after a few tough Read more...
ALSO NOTED: Lilly grabs rights to pain therapy; Study outlines billions in potential R&D savings; Takeda shares hit by FDA move
> Eli Lilly has agreed to pay India's Glenmark Pharmceuticals $45 million up front and up to $215 million in scheduled milestones for the North American, European and Japanese rights to the Read more...
SPOTLIGHT: M&A is the future for Big Pharma
What's Big Pharma's best hope for weathering the next few years of expiring patents and patchy pipelines? M&A, says London's Financial Times. That's not exactly revolutionary, of course; there Read more...
ALSO NOTED: GSK to commercialize Lunesta; second headline; and much more...
> GlaxoSmithKline has signed on to commercialize Sepracor's insomnia drug Lunesta, agreeing to pay $20 million up front and up to $155 million in total for milestones and licensing fees. Glaxo Read more...
ALSO NOTED: ImaRx prices IPO; Sepracor, Eisai sign deal for Lunesta; and much more...
> GSK has decided not to exercise its option to license Exelixis' non-small cell lung cancer drug XL647 for further development. Read more...
| Press ReleasesPRESS RELEASE: Sepracor in License Pact to Develop Antti-Epileptic Compound Sepracor in License Pact to Develop Antti-Epileptic Compound MARLBOROUGH, Mass. & S. MAMEDE DO CORONADO, Portugal -- Sepracor and Bial today announced an exclusive licensing agreement for the Read more... PRESS RELEASE: Sepracor Announces Third Quarter 2007 Results and Planned Reduction in Operating Expenses for 2008 Sepracor Announces Third Quarter 2007 Results and Planned Reduction in Operating Expenses for 2008 Financial Highlights -- Third quarter total revenues were $283.9 million -- Read more... PRESS RELEASE: Sepracor Signs Sleep Drug Partnership with GlaxoSmithKline; Sepracor to Receive Up to $155m Sepracor Signs Sleep Drug Partnership with GlaxoSmithKline; Sepracor to Receive Up to $155 Million MARLBOROUGH, Mass. & LONDON -- Sepracor and GlaxoSmithKline (GSK) today announced an agreement Read more... |
Get more Sepracor coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets